TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01444196

Intervention type: DRUG
Group type: OTHER
Intervention: Desloratadine
Description: Every day,per mouth,in the evening, for 14 +- 2 days.

Intervention type: DRUG
Group type: OTHER
Intervention: Desloratadine
Description: Every day,per mouth,in the evening, for 14 +- 2 days.
Study: NCT02331108

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selection of anesthetic induction technique
Description: Standard anesthesia care will be provided after induction based on randomization. Temperatures will be monitored every 15 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selection of anesthetic induction technique
Description: Standard anesthesia care will be provided after induction based on randomization. Temperatures will be monitored every 15 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selection of anesthetic induction technique
Description: Standard anesthesia care will be provided after induction based on randomization. Temperatures will be monitored every 15 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selection of anesthetic induction technique
Description: Standard anesthesia care will be provided after induction based on randomization. Temperatures will be monitored every 15 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selection of anesthetic induction technique
Description: Standard anesthesia care will be provided after induction based on randomization. Temperatures will be monitored every 15 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selection of anesthetic induction technique
Description: Standard anesthesia care will be provided after induction based on randomization. Temperatures will be monitored every 15 minutes
Study: NCT02763488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DelfiPTS tourniquet system

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical therapy
Study: NCT01774058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilomedin
Description: 3000ng ilomedin in 15ml salt water will be injected intraarterial into the common femoral artery over 2 minutes for one time,then the investigators will measure the blood flow volume after 5 and then after 10 minutes on the common femoral artery. The patients will be observed by the anaesthesiologist. The patient will get ilomedin one day before the surgery and then for 6 day after surgery into the vein. (10microgramm/o,5ml in 250ml salt water)
Study: NCT01476969

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic postconditioning
Description: the treatment group consisted of three 4-minute cycles left lower limb ischemia,induced by inflating a blood pressure cuff on the lower limb to 600 mmHg with an intervening 4 minutes of reperfusion ,during which time the cuff was deflate;the control group consisted of placing an uninflated cuff on the left lower limb for 24 minutes.The postconditioning protocol was applied after the aortic cross-clamping.
Study: NCT04163094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: W_ova1 Vaccine
Description: Patients will be treated with a W_ova1 vaccine that includes 3 OC TAA RNA-LPX products.
Study: NCT03288584

Intervention type: DRUG
Intervention: Tocilizumab (Actemra®)
Description: Inhibition of Interleukin-6 activity by tocilizumab (Actemra®) 150mg od, sc injection
Study: NCT01828112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: Ceritinib is the investigational treatment and is referred to as the investigational study drug and was provided as 150 mg hard gelatin capsules for oral use. The dose was 750 mg once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Description: Pemetrexed was one of the chemotherapy treatments. Pemetrexed, a reconstituted solution, was intravenously administered over 10 minutes at 500 mg/m2 every 21 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: Docetaxel was one of the chemotherapy treatments. Docetaxel, a reconstituted solution, was intravenously administered over 1 hour, at 75 mg/m2 every 21 days.
Study: NCT04010227

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Across six weekly 50-minute sessions, advanced GI cancer patients and caregivers practice various mindfulness exercises, clarify their values, and set specific goals in alignment with their values. Through in-session and home practice of skills, participants learn new and more adaptive ways to respond to unwanted internal experiences (e.g., fatigue, distress). Participants receive handouts on session topics and a compact disc (CD) that we developed to guide mindfulness practices.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education/Support
Description: Across six weekly 50-minute sessions, advanced GI cancer patients and caregivers are directed to resources for practical and health information and contact information for psychosocial services. Sessions include an orientation to the patient's medical center and treatment team, education regarding common quality-of-life concerns experienced by cancer patients and caregivers, and an overview of medical center and community resources for addressing these concerns. The therapist also describes resources for addressing financial concerns and methods of evaluating health information available via the Internet and other modalities. Participants receive handouts summarizing session topics and are asked to review them as homework.
Study: NCT02082327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV migalastat HCl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV migalastat HCl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV migalastat HCl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV migalastat HCl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV migalastat HCl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral migalastat HCl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral migalastat HCl
Study: NCT03196817

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: betamethasone dipropionate, betamethasone disodium phosphate and lidocaine 2%
Description: 6.43 mg of betamethasone dipropionate, 2.63 mg of betamethasone disodium phosphate and 0.5 ml plus lidocaine 2%

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wrist splinting
Description: Splinting only at night to maintain the wrist positioned in 15 degrees of extensionin.
Study: NCT03416049

Intervention type: DEVICE
Intervention: PEMF therapy with a high-power PEMF device
Description: The 20 participants assigned to a high-power PEMF device will treat each Venous Stasis Leg Ulcer (VSLU) area for 10 minutes twice a day.

Intervention type: DEVICE
Intervention: PEMF therapy with a medium PEMF power device
Description: The 20 participants assigned to a medium-power PEMF device will treat each VSLU area for 15 minutes twice a day.

Intervention type: DEVICE
Intervention: PEMF therapy with a low-power PEMF device
Description: The 20 participants assigned to a low-power PEMF device will treat each VSLU area for 30 minutes twice a day.

Intervention type: DEVICE
Intervention: PEMF therapy with the sham PEMF device
Description: The 20 participants assigned to the sham PEMF device will treat each VSLU area for 15 minutes twice a day.
Study: NCT03920449

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxins
Description: In group I (BT injection), 21 U will be injected in 3 divided doses through the internal anal sphincter at 3,9, and 12 o'clock. In the Egyptian market two commercial forms are available; botulinum toxin type A (Botox 100 IU/vial; Coolock, Dublin, Ireland), and abobotulinumtoxin A (Dysport 500 U/vial; Ipsen Biopharm Ltd, Wrexham, UK). In case of Dysport it should be remembered that dosing is on a ratio of approximately 1 to 3, meaning that 50 IU of Botox have the same effect as 150 IU of Dysport.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterolateral internal sphincterotomy
Description: In group II (PIAS), A 1.5 to 2-cm circumferential skin incision will be placed at 5 o'clock position outside the anal verge using an electrocautery device. Dissection will be proceeded through the intersphincteric groove to separate both IAS and external anal sphincter (EAS). Then, the IAS will be identified by its characteristic white fibers, separated from the anal mucosa, and assessed under direct vision. Subsequently, about 50 % of the IAS will be divided at 5 o'clock position and any skin tags or hypertrophied anal papillae will be removed leaving the skin incision open to allow drainage.
Study: NCT02226653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Administered orally
Study: NCT00544726

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical training

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No training
Study: NCT01897324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone (Norditropin, Novo nordisk)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone (Norditropin, Novo nordisk)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone (Norditropin, Novo nordisk)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone (Norditropin, Novo nordisk)
Study: NCT01824498

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Fat diet
Description: Low fat diet = 20% fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Fat diet
Description: Low fat diet = 20% fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Fat diet
Description: Low fat diet = 20% fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Fat diet
Description: Low fat diet = 20% fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Fat diet
Description: Low fat diet = 20% fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Fat diet
Description: Low fat diet = 20% fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Fat high n3 diet
Description: Low Fat high n3 diet = 20% fat + 3% n3

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Fat high n3 diet
Description: Low Fat high n3 diet = 20% fat + 3% n3

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Fat high n3 diet
Description: Low Fat high n3 diet = 20% fat + 3% n3

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Fat high n3 diet
Description: Low Fat high n3 diet = 20% fat + 3% n3

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Fat high n3 diet
Description: Low Fat high n3 diet = 20% fat + 3% n3

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Fat high n3 diet
Description: Low Fat high n3 diet = 20% fat + 3% n3

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fat Diet
Description: High Fat Diet = 40% fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fat Diet
Description: High Fat Diet = 40% fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fat Diet
Description: High Fat Diet = 40% fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fat Diet
Description: High Fat Diet = 40% fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fat Diet
Description: High Fat Diet = 40% fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fat Diet
Description: High Fat Diet = 40% fat
Study: NCT00850551

Intervention type: OTHER
Group type: OTHER
Intervention: Early Intervention
Description: Twice a week home spirometry and symptom assessment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early Intervention
Description: Twice a week home spirometry and symptom assessment
Study: NCT01072162

Intervention type: DRUG
Group type: OTHER
Intervention: Eltrombopag
Description: 25 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: 25 mg powder for oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: 25 mg powder for oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: 25 mg powder for oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: 25 mg powder for oral suspension
Study: NCT03741842

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COMBO-KEY
Description: The intervention will last for eight weeks with four home visits and five phone coaching sessions. It will also consist of a 4-item resource package for stroke survivors (including a stroke self-management and self-discovery workbook, a health and life planning toolkit, and videos on sharing of experience by survivors who managed their post-stroke challenges successfully, and a stroke self-management quick reference guide). A telephone hotline for survivors and caregivers to seek information and support related to stroke self-management will also be established. A programme protocol will be developed to ensure the consistent delivery of the programme.
Study: NCT03461341

Intervention type: OTHER
Intervention: High intensity postoperative oncologic surveillance
Description: High intensity surveillance protocol using routine cross-sectional imaging (computed tomography or positron emission tomography with computed tomography).
Study: NCT04358367

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Injectable Product
Description: Spinal anesthesia and intravenous dexmedetomidine (1μg/kg). The administrated drugs were slowly injected intravenously over 10 minutes then intrathecal block was achieved using 2-2.2 ml of hyperbaric bupivacaine (10 -12.5 mg) introduced at L3/4 or L4/5 interspace.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Spinal anesthesia and intravenous saline. The administrated drugs were slowly injected intravenously over 10 minutes then intrathecal block was achieved using 2-2.2 ml of hyperbaric bupivacaine (10 -12.5 mg) introduced at L3/4 or L4/5 interspace.
Study: NCT03910049

Intervention type: DRUG
Intervention: Indocyanine Green
Description: Indocyanine green will be administered intravenously to patients enrolled in this study after the completion of total thyroidectomy in order to assess the visibility of parathyroid glands and to assess the possible correlation of ICG score with post-operative parathormone levels in order to predict post-thyroidectomy hypoparathyroidism.
Study: NCT04000945

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-899
Description: Treatment with BTL-899 device, 3 therapies

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham treatment with BTL-899 device, 3 visits
Study: NCT02407509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS-6766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS-6766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS-6766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS-6766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS-6766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Study: NCT03845049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection [Eylea]
Description: Intravitreal injection of aflibercept at inclusion, M1, M2, M3 and M4. An additional injection may be planned for M5, on the decision of the clinician and on clinical arguments only.
Study: NCT02062684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blisibimod
Study: NCT03845049

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHAM injection
Description: Intravitreal injection of SHAM at inclusion, M1, M2, M3 and M4. An additional injection may be planned for M5, on the decision of the clinician and on clinical arguments only.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Examinations during study (every month)
Description: visual acuity, ocular pressure, OCT-SD, OCT-angiography and ocular fundus and a pregnancy test at M6

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Examinations during study (every month)
Description: visual acuity, ocular pressure, OCT-SD, OCT-angiography and ocular fundus and a pregnancy test at M6
Study: NCT02054468

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single-Shot Propofol
Description: Single-shot propofol induction dose (1.5-2.5mg/kg body mass)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30min infusion Propofol
Description: 30min of propofol infusion (4-6mg/kg/h)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion
Description: Remifentanil infusion (0.1-0.2µg/kg/min)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil infusion
Description: Remifentanil infusion (0.1-0.2µg/kg/min)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium (0.07mg/kg/body mass)
Description: Rocuronium (0.07mg/kg/body mass)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium (0.07mg/kg/body mass)
Description: Rocuronium (0.07mg/kg/body mass)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium (0.1mg/kg/body mass)
Description: Rocuronium (0.1mg/kg/body mass)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium (0.1mg/kg/body mass)
Description: Rocuronium (0.1mg/kg/body mass)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium (0.15mg/kg/body mass)
Description: Rocuronium (0.15mg/kg/body mass)
Study: NCT02407509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Study: NCT03012880

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV
Study: NCT04431973

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medacta Shoulder System
Description: Surgical placement of the Medacta Shoulder System prothesis on patients with pathologies requiring the insertion of a total reverse shoulder prothesis for primary omarthrosis, cuff tear arthropathy, massive cuff rupture or post instability arthropathy
Study: NCT02805517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percuvance™ Percutaneous Surgical System
Description: Patients will undergo percutaneous externally-assembled laparoscopic donor nephrectomy where one or more 3 mm instruments are added or substituted for conventional 5 or 12 mm trocars.
Study: NCT01243151

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PF-04950615 (RN316)
Description: Infusion every week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04950615 (RN316)
Description: Infusion every week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04950615 (RN316)
Description: Infusion every week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04950615 (RN316)
Description: Infusion every week
Study: NCT03012880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study: NCT01243151

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04950615 (RN316)
Description: Infusion every week
Study: NCT03240991

Intervention type: OTHER
Intervention: Quality of life
Description: Dermatology Life Quality Index, Angioedema Quality of Life Questionnaire, Angioedema Activity Score
Study: NCT02062684

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04492293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-192
Description: ICP-192 is a white, round, uncoated table
Study: NCT00979615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine HCL (Patanase) Nasal Spray, 0.6%
Description: 2 sprays/ nostril BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelastine HCl (Astelin) Nasal Spray, 137 mcg
Description: 2 sprays/ nostril BID
Study: NCT03019653

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANX-042
Description: The first 20 subjects will receive a dose 0.003 µg/kg/min by infusion, the next 20 subjects will receive a dose of 0.006 µg/kg/min, then the next 20 subjects will receive 0.01 µg/kg/min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANX-042
Description: The first 20 subjects will receive a dose 0.003 µg/kg/min by infusion, the next 20 subjects will receive a dose of 0.006 µg/kg/min, then the next 20 subjects will receive 0.01 µg/kg/min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The pharmacy created a placebo for this study is sterile Dextrose (5%) solution (D5W) 0.9% Sodium Chloride for intravenous administration to match study drug.
Study: NCT03288584

Intervention type: DRUG
Intervention: Other biological agent
Description: Other biological agent (TNFa inhibitor, abatacept, rituximab, IL-1Ra)
Study: NCT03584308

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Viusid®
Description: The VIUSID nutritional supplement is presented in the form of envelopes and will be administered orally diluted in water, juice or milk, according to the patient's preference and will be administered 3 times a day, 15 minutes before breakfast, lunch and dinner.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glizigen®
Description: The GLIZIGEN® product is presented in spray bottles and will be administered orally to swallow, away from meals 2 times a day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Viusid Placebo
Description: The placebo of VIUSID nutritional supplement is presented in the form of envelopes and will be administered orally diluted in water, juice or milk, according to the patient's preference and will be administered 3 times a day, 15 minutes before breakfast, lunch and dinner .
Study: NCT03019653

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The pharmacy created a placebo for this study is sterile Dextrose (5%) solution (D5W) 0.9% Sodium Chloride for intravenous administration to match study drug.
Study: NCT00003192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aminocamptothecin
Study: NCT01766089

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil (0.1 µg/kg/min) starting 5 min before induction of anaesthesia and continued until peritoneal closure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomidine (0.4 µg/kg/h) starting 20 before induction of anaesthesia and continued until peritoneal closure